Introduction {#Sec1}
============

Semantic variant of primary progressive aphasia (svPPA) is a subtype of frontotemporal dementia (FTD), characterized clinically by anomia and impaired single-word comprehension. It is associated with a characteristic pattern of asymmetrical antero-inferior temporal lobe atrophy \[[@CR1]--[@CR3]\]. Previous studies of svPPA have shown early left medial temporal lobe involvement, with both hippocampal and amygdalar atrophy \[[@CR4]--[@CR6]\]. However, these studies have investigated the whole hippocampus or amygdala and no previous studies have looked at the subregions of the medial temporal lobe. In this study, we therefore aimed to investigate the pattern of atrophy of the subregions of the hippocampus and the amygdala in svPPA, focusing on the involvement at different stages in order to understand the areas involved early in the disease process.

Methods {#Sec2}
=======

We reviewed the UCL Dementia Research Centre FTD MRI database to identify patients with a diagnosis of svPPA \[[@CR7]\] and a usable 3 T T1-weighted magnetic resonance (MR) scan. Twenty-four patients were identified, all with left-temporal predominant disease. Seventy-two cognitively normal subjects with a usable volumetric 3 T T1-weighted MRI were identified as controls. The study was approved by the local ethics committee, and written informed consent was obtained from all participants. The study was conducted in accordance with the Helsinki Declaration of 1975.

Based on their scores on a test of semantic knowledge (the British Picture Vocabulary Scale, BPVS, a word-picture matching task) \[[@CR8]\], we split the svPPA patients into three equal subgroups (*n* = 8 per group) of early (BPVS \> 110/150), middle (BPVS = 55--110/150) and late disease stage (BPVS \< 55/150). Patients were negative for mutations in all FTD-related genes. Two patients received post-mortem confirmation of the underlying neuropathology, both TDP-43 type C.

All patients underwent a detailed neuropsychological examination including tests of fluid intelligence (WASI Matrices), single-word comprehension (WASI Vocabulary), naming (Graded Naming Test), reading (National Adult Reading Test), verbal memory (Recognition Memory Test for Words), visual memory (Recognition Memory Test for Faces), short-term memory (forwards digit span), working memory (backwards digit span), calculation (Graded Difficulty Calculation Test), visuoperceptual function (Visual Object and Space Perception battery Object Decision subtest) and executive function (inhibition---D-KEFS Color-Word Ink Naming Test; abstract reasoning---WASI Similarities). A percentile score based on standard norms was generated for each patient, with a mean percentile score created for the early, middle and late stage groups. Assessment of behavioural symptoms was performed using the revised version of the Cambridge Behavioural Inventory (CBI-R) \[[@CR9]\]: six subscores were used (difficulties with self-care, abnormal sleep, hallucinations/delusions, disinhibition, abnormal eating behaviour, obsessive-compulsive behaviour, apathy and loss of empathy) with a percentage of the total possible subscore generated for every patient; for each stage, a mean percentage score was created. We report the cognitive and behavioural profiles at each stage for illustrative purposes (Fig. [1](#Fig1){ref-type="fig"} and Additional file [1](#MOESM1){ref-type="media"}: Table S1).Fig. 1Pattern of atrophy in amygdalar subnuclei, hippocampal subfields, cortical regions and subcortical structures across early, middle and late stages of svPPA. Colour bar denotes the percent difference in volume from controls that remained significant after correction for multiple comparisons. For illustrative purposes, we have included the changes in cognition \[mean percentile scores\] and behavioural changes \[mean percentage score in each Cambridge Behavioural Inventory subscore\] that occur at these stages. The length of the segment indicates the severity of the profile. Specifically, for the cognitive performance, the smaller the segment, the worse the performance, whilst for the behavioural symptoms, the bigger the segments, the worse the symptoms

T1-weighted MRIs were acquired using a 3-T scanner, either a Trio (Siemens, Erlangen, Germany, TR = 2200 ms, TI = 900 ms, TE = 2.9 ms, acquisition matrix = 256 × 256, spatial resolution = 1.1 mm) or a Prisma (Siemens, Erlangen, Germany, TR = 2000 ms, TI = 850 ms, TE = 2.93 ms, acquisition matrix = 256 × 256, spatial resolution = 1.1 mm). Individuals with moderate to severe vascular disease or space-occupying lesions were excluded.

Volumetric MRI scans were first bias field corrected and whole-brain parcellated using the geodesic information flow (GIF) algorithm \[[@CR10]\], which is based on atlas propagation and label fusion. The hippocampal subfields and amygdalar subregions were subsequently segmented using a customized version of the module available in FreeSurfer 6.0 \[[@CR11], [@CR12]\], to adapt the output of GIF to the FreeSurfer format. For the hippocampal subfields, we focused on seven areas: CA1, CA2/CA3, CA4, dentate gyrus, subiculum, presubiculum and the tail. We excluded from the analysis the hippocampus-amygdala transition area, the parasubiculum, the molecular layer of the hippocampus, the fimbria and the hippocampal fissure, as they were too small, or not reliably delineated on T1-weighted images. For the amygdalar subnuclei, we focused the analysis on five regions, by combining the smallest subnuclei, based on an anatomical subdivision \[[@CR13]\]: lateral nucleus, basal and paralaminar nucleus, accessory basal nucleus, cortico-amygdaloid transition area and the superficial nuclei (central nucleus, cortical nucleus, medial nucleus, anterior amygdaloid area).

For comparison with the medial temporal subregions, we extracted volumes of the following cortical regions from GIF: temporal (medial, lateral, supratemporal, temporal pole), frontal (orbitofrontal, prefrontal), parietal, occipital, insular and cingulate (anterior and posterior). We also extracted volumes of subcortical structures for the pallidum, putamen, caudate, nucleus accumbens and thalamus.

Left and right volumes were corrected for total intracranial volume (TIV), computed with SPM12 v6470 (Statistical Parametric Mapping, Wellcome Trust Centre for Neuroimaging, London, UK) running under Matlab R2014b (Math Works, Natick, MA, USA) \[[@CR14]\]. All segmentations were visually checked for quality.

Statistical analyses were performed on brain volumes (as a percentage of TIV) in STATA v14 (Stata-Corp, College Station, TX), between control and patients (early, middle and late stage groups), using a linear regression test adjusting for scanner type, TIV, gender and age. The results were corrected for multiple comparisons (Bonferroni correction): *p* \< 0.006 for amygdalar subnuclei and subcortical structures, *p* \< 0.005 for hippocampal subfields and *p* \< 0.0035 for cortical regions.

Results {#Sec3}
=======

No significant age difference was seen between any of the svPPA groups and controls \[Early: 66.9 (5.5) years, Middle: 64.5 (9.5), Late: 64.2 (5.5); Controls: 61.0 (12.1)\], *p* = 0.112, *t* test. However, there was a significant difference in gender distribution across stages \[Early: 88% male, Middle: 63% male, Late: 25% male; Controls: 40% male\], *p* = 0.032, Chi-square test.

Amygdalar subnuclei, hippocampal subfields, cortical regions, subcortical structures, neuropsychology performance and behavioural symptoms at each stage are shown in Fig. [1](#Fig1){ref-type="fig"}.

Early stage {#Sec4}
-----------

All the left amygdalar and hippocampal subregions (except for the tail) were affected (24--35% and 21--27% smaller than controls, *p* \< 0.0005) at this stage, together with the right lateral, accessory basal and superficial nuclei of the amygdala (15--23%, *p* \< 0.004) (Table [1](#Tab1){ref-type="table"}).Table 1Volumetry of amygdalar subnuclei, hippocampal subfields, cortical regions and subcortical structuresControlsEarlyMiddleControlsEarlyMiddleLeftRightMeanSD%*p*-value%*p*-value%*p*-valueMeanSD%*p*-value%*p*-value%*p*-valueAmygdalar Subnuclei Lateral nucleus  Controls0.0450.0050.0470.004  Early0.0330.010**27\< 0.0005**0.0400.006**150.003**  Middle0.0260.003**43\< 0.000523\< 0.0005**0.0350.005**25\< 0.0005120.005**  Late0.0250.003**44\< 0.000524\< 0.0005**20.7230.0300.005**36\< 0.000525\< 0.0005**140.017 Basal and paralaminar nucleus  Controls0.0330.0040.0340.003  Early0.0240.006**29\< 0.0005**0.0290.006150.012  Middle0.0180.003**46\< 0.000524\< 0.0005**0.0260.004**22\< 0.0005**80.092  Late0.0170.002**48\< 0.000527\< 0.0005**40.4830.0210.003**39\< 0.000529\< 0.000522\< 0.0005** Accessory basal nucleus  Controls0.0180.0020.0180.002  Early0.0120.004**32\< 0.0005**0.0150.004**21\< 0.0005**  Middle0.0100.002**46\< 0.0005200.002**0.0140.002**24\< 0.0005**40.373  Late0.0090.001**49\< 0.000525\< 0.0005**60.4820.0110.002**42\< 0.000527\< 0.0005240.002** Cortico-amygdaloid transition area  Controls0.0120.0020.0120.001  Early0.0090.002**24\< 0.0005**0.0110.003120.157  Middle0.0070.001**44\< 0.000527\< 0.0005**0.0090.002**24\< 0.0005**140.025  Late0.0060.001**48\< 0.000532\< 0.0005**70.3390.0080.002**36\< 0.000528\< 0.0005**160.049 Superficial nuclei (Ce, Co, Me, AAA)  Controls0.0110.0020.0120.002  Early0.0070.002**35\< 0.0005**0.0090.002**230.004**  Middle0.0060.001**47\< 0.0005180.005**0.0090.001**26\< 0.0005**40.341  Late0.0050.001**51\< 0.000525\< 0.0005**90.2750.0070.002**41\< 0.0005240.002**210.024Hippocampal Subfields CA1  Controls0.0440.0050.0470.006  Early0.0350.005**22\< 0.0005**0.0450.00850.995  Middle0.0310.007**31\< 0.0005**110.0200.0430.00780.13830.267  Late0.0290.004**36\< 0.0005180.001**70.2680.0360.006**24\< 0.000519\< 0.0005170.003** CA2/CA3  Controls0.0160.0020.0170.002  Early0.0120.002**24\< 0.0005**0.0160.00460.931  Middle0.0110.002**27\< 0.0005**30.4600.0150.003120.06470.184  Late0.0120.002**26\< 0.0005**20.518−10.9450.0130.002**24\< 0.0005190.002**130.054 CA4  Controls0.0180.0020.0190.002  Early0.0130.002**27\< 0.0005**0.0170.004**1**00.281  Middle0.0130.001**27\< 0.0005**10.3420.0160.002**150.003**50.156  Late0.0120.001**34\< 0.0005**90.00790.0660.0150.002**21\< 0.0005130.004**80.111 Dentate gyrus  Controls0.0210.0020.0210.002  Early0.0160.002**25\< 0.0005**0.0200.00570.759  Middle0.0150.002**27\< 0.0005**40.1830.0190.003130.02160.132  Late0.0140.002**32\< 0.0005**100.01160.1850.0170.003**19\< 0.0005140.003**80.117 Subiculum  Controls0.0280.0030.0290.003  Early0.0220.002**21\< 0.0005**0.0280.00610.425  Middle0.0200.003**28\< 0.0005**100.0480.0260.00580.11680.074  Late0.0200.004**31\< 0.0005130.005**40.3380.0220.005**23\< 0.000523\< 0.0005160.004** Presubiculum  Controls0.0230.0030.0220.003  Early0.0170.002**27\< 0.0005**0.0230.006−20.173  Middle0.0160.002**30\< 0.0005**50.3620.0210.00750.94260.267  Late0.0160.003**33\< 0.0005**80.04530.2450.0180.005**190.001200.001**150.015 Hippocampal tail  Controls0.0410.0050.0410.005  Early0.0340.006180.0190.0430.010−40.055  Middle0.0300.005**28\< 0.0005**120.0260.0420.010−20.37120.41  Late0.0290.006**29\< 0.0005**130.00920.6240.0370.00880.084120.008100.054Cortical Regions Orbitofrontal  Controls0.6970.0470.7160.048  Early0.6820.04520.9340.7270.057**−20.158**  Middle0.6290.089**100.001**80.0150.7160.046**00.80610.362**  Late0.6370.06390.00970.062−10.6120.6970.078**30.64740.16630.604** Prefrontal cortex  Controls4.2160.2304.3220.224  Early4.0870.33730.6914.2990.37910.545  Middle4.0450.52940.11210.3734.3800.369−10.506−20.977  Late3.8060.250**100.002**70.04760.2454.1190.26950.20140.16860.153 Anterior cingulate  Controls0.3820.0390.2830.042  Early0.3150.041**180.001**0.2890.046−20.339  Middle0.3000.068**22\< 0.0005**50.3110.3180.069−130.008−100.204  Late0.2550.026**33\< 0.0005190.002**150.0230.2880.058−20.96800.45790.047 Posterior cingulate  Controls0.3590.0380.3430.035  Early0.3500.02030.6090.3680.019−70.009  Middle0.3320.02570.06550.3200.3650.028−60.02210.747  Late0.3370.02860.16940.535−10.7280.3610.047−50.15020.34810.523 Parietal  Controls3.2240.2113.1860.229  Early3.1430.22930.5383.2160.248−10.049  Middle3.1470.24920.70900.4503.2720.200−30.053−20.944  Late2.9930.234**70.003**50.00850.0463.1420.21310.79320.09640.105 Occipital  Controls2.4730.2072.5640.205  Early2.3930.22730.8352.5380.19510.575  Middle2.3950.15530.55200.7762.5520.17500.697−10.887  Late2.4320.14820.733−20.926−20.8532.5720.14700.796−10.817−10.924 Insula  Controls0.3700.0350.3810.039  Early0.2810.032**24\< 0.0005**0.3430.049100.110  Middle0.2600.036**30\< 0.0005**70.0640.3370.038120.00720.425  Late0.2290.021**38\< 0.000518\< 0.0005**120.0130.2670.039**30\< 0.000522\< 0.000521\< 0.0005** Medial temporal  Controls1.0120.0621.0410.067  Early0.7850.057**22\< 0.0005**0.9810.07060.076  Middle0.7300.056**28\< 0.0005**70.0420.9150.070**12\< 0.0005**70.044  Late0.7430.058**27\< 0.0005**50.088−20.7870.7910.074**24\< 0.000519\< 0.000514\< 0.0005** Lateral temporal  Controls2.3040.1532.3450.143  Early1.6520.201**28\< 0.0005**2.2310.13450.133  Middle1.5540.150**33\< 0.0005**60.0842.1370.099**9\< 0.0005**40.105  Late1.3840.159**40\< 0.000516\< 0.0005**110.0261.8640.217**21\< 0.000516\< 0.000513\< 0.0005** Temporal pole  Controls0.4880.0560.4770.055  Early0.2610.066**47\< 0.0005**0.4130.071**130.006**  Middle0.2310.035**53\< 0.0005**120.1870.3520.049**26\< 0.0005**150.019  Late0.2280.029**53\< 0.0005**130.32410.7660.2870.038**40\< 0.000530\< 0.0005**180.048 Supratemporal  Controls0.4300.0500.3690.039  Early0.3480.037**19\< 0.0005**0.3570.04530.910  Middle0.3360.046**22\< 0.0005**40.3590.3680.04000.718−30.855  Late0.3010.056**30\<0.0005**140.017100.1220.3220.054**130.004**100.028120.016Subcortical Structures Nucleus accumbens  Controls0.0400.0030.0380.003  Early0.0350.003**13\<0.0005**0.0350.00390.048  Middle0.0340.005**15\<0.0005**30.2350.0360.00450.155−40.638  Late0.0300.003**24\<0.0005130.001**100.0190.0320.004**15\<0.0005**70.026110.007 Caudate  Controls0.2370.0260.2480.024  Early0.2210.02070.5080.2350.02650.598  Middle0.2220.02660.35000.8510.2370.02440.507−10.929  Late0.2070.030**120.001**60.03770.0530.2170.036**120.001**80.04480.050 Pallidum  Controls0.1290.0140.1300.013  Early0.1140.007120.0100.1190.00780.123  Middle0.1130.008**12\<0.0005**10.1600.1190.00880.00400.303  Late0.1040.009**19\<0.0005**90.01680.2700.1110.011**14\<0.0005**60.05470.336 Putamen  Controls0.3070.0310.3050.031  Early0.2680.018130.0110.2890.01650.981  Middle0.2550.023**17\<0.0005**50.0440.2770.02390.01940.081  Late0.2370.018**23\<0.0005110.001**70.1440.2610.022**14\<0.0005100.002**60.142 Thalamus  Controls0.4000.0350.3920.039  Early0.3570.024110.0240.3800.03230.279  Middle0.3620.02990.008−20.7910.3870.03610.258−20.992  Late0.3640.027**9\<0.0005**−20.169−10.2550.3880.02710.226−20.09300.086Values denote mean and standard deviation (SD) volumes as the percentage of the total intracranial volume (TIV) or difference (%). *p* values denote significance on linear regression test. Bold represents a significant difference between the groups after correcting for multiple comparisons

Outside of the medial temporal lobe, on the left, all the temporal cortical regions (19--47%, *p* \< 0.0005) were affected as well as the anterior cingulate (18%, *p* = 0.001) and insula (24%, *p* \< 0.0005). The left nucleus accumbens was the only other subcortical structure affected (13%, *p* \< 0.0005). Apart from the affected amygdalar subnuclei, the only other right hemisphere structure affected at this stage was the temporal pole (13%, *p* = 0.006).

Cognitively, patients showed severely impaired naming already, with relatively preserved working memory, abstract reasoning and fluid intelligence. Behavioural symptoms were mild and mainly related to abnormal eating behaviour, apathy and abnormal sleep.

Middle stage {#Sec5}
------------

At this stage, the left hippocampal tail became affected (28%, *p* \< 0.0005), together with the other right amygdalar nuclei (22--26%, *p* \< 0.0005) and the right CA4 region of the hippocampus (15%, *p* = 0.003).

Cortically, the left orbitofrontal lobe was affected at this stage along with more posterior temporal structures on the right: lateral and medial temporal cortices (9--12%, *p* \< 0.0005). Subcortically, the left pallidum and putamen were affected (12--17%, *p* \< 0.0005) and the right pallidum (8%).

Cognitively, single-word comprehension and reading became increasingly impaired, but working memory, short-term memory and abstract reasoning remained relatively intact. Behavioural symptoms increased with the presence of obsessive-compulsive behaviour and loss of empathy as well as abnormal eating behaviour, apathy and disinhibition.

Late stage {#Sec6}
----------

In the late stage, the remaining right hippocampal regions (except the tail) (19--24%, *p* \< 0.001) became affected.

Cortically, spread to the left prefrontal and parietal cortices was seen whilst on the right, the insula (30%) and supratemporal cortex (13%, *p* \< 0.004) were affected. Subcortically, the left caudate, thalamus and right nucleus accumbens, caudate and putamen were affected (12--15%).

At this stage, all cognitive domains were severely impaired except for short-term and working memory, abstract reasoning and fluid intelligence. Severe behavioural symptoms were seen.

Discussion {#Sec7}
==========

Using advanced subregional segmentation, we were able to detect early involvement in the right hemisphere in svPPA, with progression of atrophy through the medial temporal lobes as the disease moves from early to middle to late stage.

Extensive medial temporal atrophy is seen on the left in most amygdalar and hippocampal subregions at the earliest stage of svPPA, co-incidental with the involvement of all of the temporal cortices on the left. This is consistent with previous studies showing that even at first clinical presentation, significant left temporal lobe atrophy is present \[[@CR1], [@CR15]\].

Previous studies have not shown early involvement of the right medial temporal structures. In this study, the earliest subnuclei affected on the right were the accessory basal, lateral and superficial nuclei of the amygdala. These subnuclei are interconnected and receive input from the temporal pole and the hippocampus (also affected on the right in the early stage) as well as other parts of the temporal and frontal cortices and the nucleus accumbens \[[@CR13], [@CR16]\]. The ability to use advanced subregional segmentation techniques in this study allows early detection of right medial temporal atrophy.

The cognitive and behavioural correlates of the individual right amygdalar subnuclei are poorly studied, but prior studies of the whole amygdala implicate the right side as being important in the processing of emotional information \[[@CR17], [@CR18]\]. In our study, loss of empathy is mildly affected at the earliest stage (Fig. [1](#Fig1){ref-type="fig"}): this is likely to represent an impairment of self-knowledge, a process that requires the linking of emotions with semantics, and has previously been shown to be associated with right temporal lobe atrophy including the amygdala \[[@CR19]\]. The particular amygdalar subnuclei affected early are part of the limbic network and therefore likely to be intrinsically involved in emotion processing \[[@CR16]\].

Of all the medial temporal subregions, the hippocampal tail is preserved until the later stages of svPPA. This is in line with previous studies, where the posterior temporal lobe is spared and an antero-posterior gradient is present \[[@CR20], [@CR21]\]. Indeed, svPPA patients typically show intact episodic memory and spatial navigation, functions typically linked to the hippocampal tail. Consistent with the theory of svPPA as a network-opathy \[[@CR22]\], the first hippocampal region to become affected on the right is CA4, an area highly connected to the temporal cortex and amygdala \[[@CR23]\].

Limitations of the study include using cross-sectional data with staging of the disease by impairment on a task of semantic knowledge and the small number of svPPA cases. Further studies would benefit from the analysis of longitudinal data from a larger sample to see whether the same pattern is seen. Despite the gold standard still being manual segmentation of dedicated MRIs or on brain tissue post-mortem, these automated methods included in this study have been previously validated and proven reliable to delineate the subregions on T1-MRI (Dice coefficients \> 0.86; ICC 0.88--0.93) \[[@CR10]--[@CR12], [@CR24], [@CR25]\]. Moreover, in this study, we carefully excluded small subregions and combined together groups of nuclei to improve the anatomical validity. Automated segmentations will play a key role in the future, as manual segmentations are likely to be unfeasible for large cohorts of patients.
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===============

 {#Sec8}

Additional file 1:**Table S1.** Cognitive and behavioural variables for the svPPA patients. *p* values denote significance on Kruskal-Wallis test among the three groups. (DOCX 17 kb)
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